{"id":18839,"date":"2018-09-12T09:00:44","date_gmt":"2018-09-12T07:00:44","guid":{"rendered":"https:\/\/wordpress-783423-2671269.cloudwaysapps.com\/?p=18839"},"modified":"2022-03-10T05:54:37","modified_gmt":"2022-03-10T04:54:37","slug":"12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018","status":"publish","type":"post","link":"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/","title":{"rendered":"<span id=\"2018\" class=\"Postdate\">September 12, 2018<\/span> | Dermapharm Holding SE publishes report for first half of 2018"},"content":{"rendered":"<p>[et_pb_section admin_label=&#8221;section&#8221;][et_pb_row admin_label=&#8221;Zeile&#8221; make_fullwidth=&#8221;off&#8221; use_custom_width=&#8221;off&#8221; width_unit=&#8221;on&#8221; use_custom_gutter=&#8221;off&#8221; custom_padding=&#8221;||0px|&#8221; padding_mobile=&#8221;off&#8221; allow_player_pause=&#8221;off&#8221; parallax=&#8221;off&#8221; parallax_method=&#8221;off&#8221; make_equal=&#8221;off&#8221; parallax_1=&#8221;off&#8221; parallax_method_1=&#8221;off&#8221; parallax_2=&#8221;off&#8221; parallax_method_2=&#8221;off&#8221; column_padding_mobile=&#8221;on&#8221;][et_pb_column type=&#8221;1_2&#8243;][et_pb_text admin_label=&#8221;Text&#8221; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<style>\n.zur\u00fcckbutton:before {\n    display: inline-block;\n    font-family: \"ETmodules\";\n    content: \"4a\";\n    color: #00225f;\n    margin-right: 7px;\n}\n.zur\u00fcckbutton:hover:before {\n    display: inline-block;\n    font-family: \"ETmodules\";\n    content: \"4a\";\n    color: #d85710;\n    margin-right: 7px;\n}\n<\/style>\n<h1 style=\"text-align: justify;\">Corporate news<\/h1>\n<p> <a class=\"zur\u00fcckbutton\" href=\"https:\/\/dev.cometis.de\/en\/publication-archive-dermapharm\">to the archive<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243;][et_pb_image admin_label=&#8221;Bild&#8221; src=&#8221;https:\/\/dev.cometis.de\/wp-content\/uploads\/2018\/08\/autodoc_Logo_Wei%C3%9F_2-7.png&#8221; show_in_lightbox=&#8221;off&#8221; url_new_window=&#8221;off&#8221; use_overlay=&#8221;off&#8221; animation=&#8221;off&#8221; sticky=&#8221;off&#8221; align=&#8221;right&#8221; force_fullwidth=&#8221;off&#8221; always_center_on_mobile=&#8221;on&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<p>[\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=&#8221;row&#8221;][et_pb_column type=&#8221;4_4&#8243;][et_pb_text admin_label=&#8221;Text&#8221; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<h1>Dermapharm Holding SE publishes report for first half of 2018<\/h1>\n<ul>\n<li>Group revenues increased by 19.7% to EUR 280.3 million <\/li>\n<li>Adjusted EBITDA rose by 29.9% to EUR 70.9 million; EBITDA margin improved to 25.3%<\/li>\n<li>New growth opportunities thanks to the acquisitions of Strathmann and Trommsdorff, organic growth and successfully introduced proprietary developments<\/li>\n<li>Management Board confirms forecast for fiscal year 2018<\/li>\n<\/ul>\n<p>Gr\u00fcnwald, September 12, 2018 \u2013 Dermapharm Holding SE (\u201cDermapharm\u201d), a leading producer of patent-free branded pharmaceuticals for select therapeutic areas based in Germany with a growing international presence, published its report for the first six months of 2018 today. The company increased its revenues by 19.7% to EUR 280.3 million in the reporting period (previous year: EUR 234.2 million). Earnings before interest, taxes, depreciation and amortization (EBITDA) adjusted for IPO preparations and the acquisitions of Strathmann and Trommsdorff in the amount of EUR 3.8 million increased by 29.9% to EUR 70.9 million (same period of the previous year: EUR 54.6 million). Accordingly, the adjusted EBITDA margin was 25.3%, 2 percentage points above the margin of the previous year. Unadjusted EBITDA amounted to EUR 67.1 million and the unadjusted EBITDA margin was 23.9%. \u201cThe figures for the first half of 2018 reflect the success of our consistent growth strategy. With our latest acquisitions of Strathmann and Trommsdorff, we have not only expanded our current portfolio to include established brand products such as Keltican\u00ae forte, but have also gained a significant market share in the new therapeutic area of pain treatment. Ambitious products such as Myopridin\u00ae and Ebenol\u00ae from Strathmann ideally complement our portfolio in this therapeutic area. This new market rounds off our strategic therapeutic areas, which also include dermatologics, systemic corticoids, women\u2019s healthcare, ophthalmologics and vitamins, minerals and enzymes. In addition, Dermapharm achieved further market approvals in the first half of the year, such as Verrucutan\u00ae, Calcilac mono\u00ae and Summavit materna\u00ae, and is also working on more than 40 ongoing development projects. We have also succeeded in opening up new European markets for our hyperthermia medical devices bite away\u00ae and Herpotherm\u00ae in Northern, Eastern and Central Europe and plan to market the products in the UK, Western Europe, Asia and the US in the future,\u201d commented Dr. Hans-Georg Feldmeier, CEO of Dermapharm Holding SE. Revenues in the segment \u201cBranded pharmaceuticals and other healthcare products\u201d rose by 48.1% to EUR 163.2 million (same period of the previous year: EUR 110.2 million). Therefore, reported EBITDA in this segment increased by 25.7% to EUR 64.5 million (same period of the previous year: EUR 51.3 million). This increase is due in large part to positive gross profit development along with reductions in expenditures for discounts from direct contracts with health insurance companies and in material costs. Due to the integration of the new acquisitions, the segment\u2019s EBITDA margin of 39.5% was below the corresponding prior-year figure of 46.6%. In the \u201cParallel import business\u201d segment, revenues decreased by 5.6% to EUR 117.1 million in the reporting period (same period of the previous year: EUR 124.0 million). This decline was caused primarily by the concentration on high-margin yet small-volume pharmaceuticals. EBITDA for the Parallel import business increased significantly by 63.1% to EUR 5.4 million in the first half of the year (same period of the previous year: EUR 3.3 million). Dermapharm achieved this by optimizing its product portfolio, increasing its gross profit margin through demand-oriented purchasing and constant cost optimization by relocating its reimported narcotics business in-house. The EBITDA margin in this segment increased accordingly from 2.6% in the prior-year period to 4.6%. In light of the positive business development in the first half of 2018 and assuming positive market prospects, the Management Board confirms its full-year forecast of revenue growth of 20 to 25% and an improvement in EBITDA of 22 to 27% over fiscal year 2017.<br \/>\nThe complete half-year report is available as of today online at ir.dermapharm.com.<\/p>\n<p><strong>Key financial figures for H1 2018 year-on-year<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td>in EUR million<\/td>\n<td> H1\/2018<\/td>\n<td> H1\/2017<\/td>\n<td> Change<\/td>\n<\/tr>\n<tr>\n<td>Group revenues<\/td>\n<td>280,3 <\/td>\n<td>234,2 <\/td>\n<td>19,7%<\/td>\n<\/tr>\n<tr>\n<td>Branded pharmaceuticals and other healthcare products<\/td>\n<td> 163,2<\/td>\n<td> 110,2<\/td>\n<td> + 48,1%<\/td>\n<\/tr>\n<tr>\n<td>Parallel import business<\/td>\n<td> 117,1 <\/td>\n<td>124,0<\/td>\n<td> &#8211; 5,6%<\/td>\n<\/tr>\n<tr>\n<td>Reconciliation \/ Group Holding<\/td>\n<td>&#8211;<\/td>\n<td> &#8211;<\/td>\n<td> &#8211;<\/td>\n<\/tr>\n<tr>\n<td>Adjusted\u00b9 Group EBITDA<\/td>\n<td>70,9<\/td>\n<td> 54,6 <\/td>\n<td>+ 29,9%<\/td>\n<\/tr>\n<tr>\n<td>Adjusted\u00b9 EBITDA margin (in %)<\/td>\n<td> 25,3 <\/td>\n<td>23,3<\/td>\n<td> + 2,0pp<\/td>\n<\/tr>\n<tr>\n<td>Group EBITDA<\/td>\n<td>67,1<\/td>\n<td> 54,6 <\/td>\n<td>+ 22,9%<\/td>\n<\/tr>\n<tr>\n<td>Branded pharmaceuticals and other healthcare products<\/td>\n<td>64,5<\/td>\n<td> 51,3 <\/td>\n<td>+ 25,7%<\/td>\n<\/tr>\n<tr>\n<td>Parallel import business<\/td>\n<td>5,4<\/td>\n<td> 3,3 <\/td>\n<td>+ 63,1%<\/td>\n<\/tr>\n<tr>\n<td>Reconciliation \/ Group Holding<\/td>\n<td>&#8211; 2,7 <\/td>\n<td>&#8211;<\/td>\n<td> &#8211;<\/td>\n<\/tr>\n<tr>\n<td>EBITDA Margin (in %)<\/td>\n<td>23,9 <\/td>\n<td>23,3 <\/td>\n<td>+ 0,6pp<\/td>\n<\/tr>\n<tr>\n<td>Branded pharmaceuticals and other healthcare products<\/td>\n<td>39,5<\/td>\n<td> 46,6 <\/td>\n<td>&#8211; 7,1pp<\/td>\n<\/tr>\n<tr>\n<td>Parallel import business<\/td>\n<td> 4,6 <\/td>\n<td>2,6<\/td>\n<td> + 2pp<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\u00b9 H1\/2018 EBITDA adjusted for one-off costs in connection with the IPO and the acquisitions of Strathmann and Trommsdorff in the amount of EUR 3.8 million<\/p>\n<p><strong>Company profile:<\/strong><br \/>\nDermapharm \u2013 Pharmaceutical Excellence &#8220;Made in Germany&#8221; Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Gr\u00fcnwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company\u2019s integrated business model comprises inhouse development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm holds approximately 950 marketing authorizations (Arzneimittelzulassungen) for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This assortment makes the company unique. In addition to Germany, the company\u2019s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm\u2019s business model also includes a parallel import business, which operates under the \u201caxicorp\u201d brand. Based on revenues, Dermapharm was among the top five parallel import companies in Germany in the first half-year 2018. With a consistent development strategy and numerous successful product and company acquisitions over the past 25 years, Dermapharm has continuously optimized its business and provided external growth impulses in addition to organic growth. Dermapharm intends to continue this profitable growth course in the future. The company is focusing on three strategic growth drivers: in-house development of new products, increase of its international footprint and further acquisitions. These include the acquisition of the pharmaceuticals manufacturer and distributor Trommsdorff in January 2018, whose portfolio includes the well-known brands Keltican\u00ae forte and Tromcardin\u00ae complex.<\/p>\n<p>Corporate News<br \/>\nContact<br \/>\ncometis AG<br \/>\nClaudius Krause<br \/>\nPhone: +49 (0)611 \u2013 205855-28<br \/>\nFax: +49 (0)611 \u2013 205855-66<br \/>\nEmail: ir@dermapharm.de<\/p>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;Text&#8221; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<div class=\"leseprobe-archiv\"><a title=\"Post as PDF\" href=\"https:\/\/ir.dermapharm.de\/pdf\/20180912_CN_Dermapharm_H1_2018_financial_figures.pdf\" target=\"_blank\" rel=\"noopener\">Post as PDF<\/a><\/div>\n<style>\n.leseprobe-archiv {\n    color: #00225f !important;\n    border-color: #00225f;\n    position: relative;\n    padding: 0.3em 1em;\n    border: 1px solid;\n    -webkit-border-radius: 3px;\n    -moz-border-radius: 3px;\n    border-radius: 3px;\n   -webkit-transition: all 0.2s;\n    -moz-transition: all 0.2s;\n    transition: all 0.2s;\n    padding:10px;\n    width: 19%;\n    text-align: center;\n    margin-right: 10px;\n    float:left;\n}\n.leseprobe-archiv:hover {\n    background-color: #eee;\n    border-color: #ffffff;\n    cursor: pointer;\n}\n<\/style>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Corporate news to the archive Dermapharm Holding SE publishes report for first half of 2018 Group revenues increased by 19.7% to EUR 280.3 million Adjusted EBITDA rose by 29.9% to EUR 70.9 million; EBITDA margin improved to 25.3% New growth opportunities thanks to the acquisitions of Strathmann and Trommsdorff, organic growth and successfully introduced proprietary [&hellip;]<\/p>\n","protected":false},"author":24813,"featured_media":54374,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"[et_pb_section admin_label=\"section\"][et_pb_row admin_label=\"Zeile\" make_fullwidth=\"off\" use_custom_width=\"off\" width_unit=\"on\" use_custom_gutter=\"off\" custom_padding=\"||0px|\" padding_mobile=\"off\" allow_player_pause=\"off\" parallax=\"off\" parallax_method=\"off\" make_equal=\"off\" parallax_1=\"off\" parallax_method_1=\"off\" parallax_2=\"off\" parallax_method_2=\"off\" column_padding_mobile=\"on\"][et_pb_column type=\"1_2\"][et_pb_text admin_label=\"Text\" background_layout=\"light\" text_orientation=\"left\" use_border_color=\"off\" border_color=\"#ffffff\" border_style=\"solid\"]\r\n\r\n<style>\r\n.zur\u00fcckbutton:before {\r\n    display: inline-block;\r\n    font-family: \"ETmodules\";\r\n    content: \"4a\";\r\n    color: #00225f;\r\n    margin-right: 7px;\r\n}\r\n.zur\u00fcckbutton:hover:before {\r\n    display: inline-block;\r\n    font-family: \"ETmodules\";\r\n    content: \"4a\";\r\n    color: #d85710;\r\n    margin-right: 7px;\r\n}\r\n<\/style>\r\n<h1 style=\"text-align: justify;\">Corporate News<\/h1> <a class=\"zur\u00fcckbutton\" href=\"https:\/\/dev.cometis.de\/veroeffentlichungsarchiv-dermapharm\">zum Archiv<\/a>\r\n\r\n[\/et_pb_text][\/et_pb_column][et_pb_column type=\"1_2\"][et_pb_image admin_label=\"Bild\" src=\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2018\/08\/autodoc_Logo_Wei%C3%9F_2-7.png\" show_in_lightbox=\"off\" url_new_window=\"off\" use_overlay=\"off\" animation=\"off\" sticky=\"off\" align=\"right\" force_fullwidth=\"off\" always_center_on_mobile=\"on\" use_border_color=\"off\" border_color=\"#ffffff\" border_style=\"solid\"]\r\n\r\n\r\n\r\n[\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=\"row\"][et_pb_column type=\"4_4\"][et_pb_text admin_label=\"Text\" background_layout=\"light\" text_orientation=\"left\" use_border_color=\"off\" border_color=\"#ffffff\" border_style=\"solid\"]\r\n\r\n<h1>Dermapharm Holding SE ver\u00f6ffentlicht Bericht f\u00fcr das erste Halbjahr 2018<\/h1>\r\n<ul>\r\n\t<li>Konzernumsatz um 19,7% auf 280,3 Mio. \u20ac gesteigert<\/li>\r\n\r\n\t<li>Bereinigtes EBITDA um 29,9% auf 70,9 Mio. \u20ac gestiegen; EBITDA-Marge auf 25,3% verbessert<\/li>\r\n\r\n\t<li>Mit Akquisitionen von Strathmann und Trommsdorff, organischem Wachstum und erfolgreich eingef\u00fchrten Eigenentwicklungen Wachstumschancen weiter erh\u00f6ht<\/li>\r\n\r\n\t<li>Vorstand best\u00e4tigt Prognose f\u00fcr das Gesamtjahr 2018<\/li>\r\n<\/ul>\r\n\r\n\r\n\r\nGr\u00fcnwald, 12. September 2018 \u2013 Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete in Deutschland mit wachsender internationaler Pr\u00e4senz, ver\u00f6ffentlicht heute den Bericht \u00fcber die ersten sechs Monate 2018. Das Unternehmen konnte den Umsatz im Berichtszeitraum um 19,7% auf 280,3 Mio. \u20ac steigern (Vorjahreszeitraum: 234,2 Mio. \u20ac). Zugleich erh\u00f6hte sich das um Einmalkosten im Zusammenhang mit der B\u00f6rsennotierung und den Akquisitionen von Strathmann und Trommsdorff in H\u00f6he von 3,8 Mio. \u20ac bereinigte Ergebnis vor Zinsen, Steuern und Abschreibungen (EBITDA) um 29,9% auf 70,9 Mio. \u20ac (Vorjahreszeitraum: 54,6 Mio. \u20ac). Die bereinigte EBITDA-Marge lag \r\nentsprechend bei 25,3% und damit 2 Prozentpunkte \u00fcber der Marge des Vorjahres. Das unbereinigte EBITDA betrug 67,1 Mio. \u20ac, die unbereinigte EBITDA-Marge lag bei 23,9%. Dr. Hans-Georg Feldmeier, Vorstandsvorsitzender der Dermapharm Holding SE, kommentiert: \u201eDie Zahlen f\u00fcr das erste Halbjahr 2018 spiegeln den Erfolg unserer konsequenten Wachstumsstrategie wider. Mit unseren neuesten Akquisitionen Strathmann und Trommsdorff konnten wir nicht nur das bestehende Portfolio um etablierte Markenprodukte wie z.B. Keltican\u00ae forte erweitern, sondern auch einen bedeutenden Marktanteil im neuen Therapiegebiet Schmerzbehandlung hinzugewinnen. Ambitionierte Produkte wie Myopridin\u00ae und Ebenol\u00ae von Strathmann erg\u00e4nzen unser Portfolio ideal in diesem Therapiegebiet. Dieser neue Markt komplettiert unsere strategischen Therapiegebiete, zu denen au\u00dferdem Dermatologie, Systemische Kortikoide, Frauenheilkunde, Augentherapeutika und Vitamine\/ Mineralstoffe\/ Enzyme geh\u00f6ren. Im ersten Halbjahr konnten wir zudem weitere Marktzulassungen erreichen, wie zum Beispiel Verrucutan\u00ae, Calcilac mono\u00ae oder Summavit materna\u00ae, w\u00e4hrend wir dar\u00fcber hinaus noch an mehr als 40 laufenden Entwicklungsprojekten arbeiten. Ebenso ist es uns gelungen, f\u00fcr unsere hyperthermischen Medizinprodukte bite away\u00ae und Herpotherm\u00ae neue M\u00e4rkte in Nord-, Ost- und Mitteleuropa zu erschlie\u00dfen. Im n\u00e4chsten Schritt planen wir, diese Produkte auch in UK, Westeuropa, Asien und Amerika zu vertreiben.\u201c Der Umsatz im Segment \u201eMarkenarzneimittel und andere Gesundheitsprodukte\u201c konnte um 48,1% auf\r\n163,2 Mio. \u20ac (Vorjahreszeitraum: 110,2 Mio. \u20ac) gesteigert werden. Somit erh\u00f6hte sich das ausgewiesene EBITDA des Segments um 25,7% auf 64,5 Mio. \u20ac (Vorjahreszeitraum: 51,3 Mio. \u20ac). Diese Steigerung ist ma\u00dfgeblich auf die positive Entwicklung des Rohertrags bei gleichzeitiger Senkung der Aufwendung f\u00fcr Rabatte aus Direktvertr\u00e4gen mit Krankenkassen sowie der Materialkosten zur\u00fcckzuf\u00fchren. Bedingt durch die Integration der Neuakquisitionen lag die EBITDAMarge des Segments mit 39,5% unter dem entsprechenden Vorjahreswert von 46,6%. \r\nIm Segment \u201eParallelimportgesch\u00e4ft\u201c verringerte sich der Umsatz im Berichtszeitraum um 5,6% auf 117,1 Mio. \u20ac (Vorjahreszeitraum: 124,0 Mio. \u20ac). Dieser R\u00fcckgang resultierte im Wesentlichen aus der Konzentration auf margenstarke, jedoch kleinvolumige Pr\u00e4parate. Das EBITDA im Parallelimportgesch\u00e4ft konnte im ersten Halbjahr signifikant um 63,1% auf 5,4 Mio. \u20ac (Vorjahreszeitraum: 3,3 Mio. \u20ac) gesteigert werden. Dies erreichte Dermapharm durch die Optimierung des Produktportfolios, die Steigerung der Rohertragsmarge durch einen bedarfsgerechten Einkauf sowie eine stetige Kostenoptimierung durch die Inhouse-Verlagerung des Gesch\u00e4fts mit reimportierten Bet\u00e4ubungsmitteln. Entsprechend erh\u00f6hte sich die EBITDA-Marge in diesem Segment von 2,6% im Vorjahreszeitraum auf 4,6%.\r\nAngesichts der positiven Gesch\u00e4ftsentwicklung im ersten Halbjahr 2018 sowie unter Annahme positiver Marktaussichten best\u00e4tigt der Vorstand die Gesamtjahresprognose und rechnet weiterhin mit Corporate News\r\neinem Umsatzwachstum von 20 bis 25% und einer Verbesserung des EBITDA von 22 bis 27% im Vergleich zum Gesch\u00e4ftsjahr 2017. \r\nDer vollst\u00e4ndige Halbjahresbericht ist ab heute auf der Internetseite ir.dermapharm.com verf\u00fcgbar. \r\n\r\n<strong>Finanzkennzahlen H1 2018 im Jahresvergleich<\/strong>\r\n\r\n<table>\r\n<tbody><tr><td>in Mio. EUR<\/td><td> H1\/2018<\/td><td> H1\/2017<\/td><td> Ver\u00e4nderung<\/td><\/tr>\r\n<tr><td>Konzernumsatz<\/td><td>280,3 <\/td><td>234,2 <\/td><td>19,7%<\/td><\/tr>\r\n<tr><td>Markenarzneimittel und andere Gesundheitsprodukte<\/td><td> 163,2<\/td><td> 110,2<\/td><td> + 48,1%<\/td><\/tr>\r\n<tr><td>Parallelimportgesch\u00e4ft<\/td><td> 117,1 <\/td><td>124,0<\/td><td> - 5,6%<\/td><\/tr>\r\n<tr><td>\u00dcberleitung \/ Konzernholding <\/td><td>-<\/td><td> -<\/td><td> -<\/td><\/tr>\r\n<tr><td>Bereinigtes\u00b9 Konzern-EBITDA <\/td><td>70,9<\/td><td> 54,6 <\/td><td>+ 29,9%<\/td><\/tr>\r\n<tr><td>Bereinigte\u00b9 EBITDA-Marge (in %)<\/td><td> 25,3 <\/td><td>23,3<\/td><td> + 2,0pp<\/td><\/tr>\r\n<tr><td>Konzern-EBITDA <\/td><td>67,1<\/td><td> 54,6 <\/td><td>+ 22,9%<\/td><\/tr>\r\n<tr><td>Markenarzneimittel und andere Gesundheitsprodukte <\/td><td>64,5<\/td><td> 51,3 <\/td><td>+ 25,7%<\/td><\/tr>\r\n<tr><td>Parallelimportgesch\u00e4ft <\/td><td>5,4<\/td><td> 3,3 <\/td><td>+ 63,1%<\/td><\/tr>\r\n<tr><td>\u00dcberleitung \/ Konzernholding <\/td><td>- 2,7 <\/td><td>-<\/td><td> -<\/td><\/tr>\r\n<tr><td>EBITDA-Marge (in %) <\/td><td>23,9 <\/td><td>23,3 <\/td><td>+ 0,6pp<\/td><\/tr>\r\n<tr><td>Markenarzneimittel und andere Gesundheitsprodukte <\/td><td>39,5<\/td><td> 46,6 <\/td><td>- 7,1pp<\/td><\/tr>\r\n<tr><td>Parallelimportgesch\u00e4ft<\/td><td> 4,6 <\/td><td>2,6<\/td><td> + 2pp<\/td><\/tr>\r\n<\/tbody><\/table>\r\n\u00b9 EBITDA H1\/2018 um Einmalkosten im Zusammenhang mit der B\u00f6rsennotierung und den Akquisitionen von Strathmann und Trommsdorff in H\u00f6he von 3,8 Mio. \u20ac bereinigt\r\n\r\n<strong>Unternehmensprofil:<\/strong>\r\nDermapharm - Pharmazeutische Exzellenz \"Made in Germany\" Dermapharm ist ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte M\u00e4rkte in Deutschland. Die 1991 gegr\u00fcndete Gesellschaft hat ihren Sitz in Gr\u00fcnwald bei M\u00fcnchen und ihren Hauptproduktionsstandort in Brehna bei Leipzig. Das integrierte Gesch\u00e4ftsmodell der Gesellschaft umfasst die hausinterne Entwicklung, eigene Produktion sowie den Vertrieb von Arzneimitteln und anderen Gesundheitsprodukten f\u00fcr ausgew\u00e4hlte M\u00e4rkte durch einen pharmazeutisch geschulten Au\u00dfendienst. Dermapharm verf\u00fcgt \u00fcber rund 950 Arzneimittelzulassungen f\u00fcr mehr als 250 Wirkstoffe, die als Arzneimittel bzw. Nahrungserg\u00e4nzungsmittel oder Erg\u00e4nzende Bilanzierte Di\u00e4ten vertrieben werden. Dieses Sortiment macht das Unternehmen unverwechselbar. Zu den Kernm\u00e4rkten der Gesellschaft geh\u00f6ren derzeit neben Deutschland auch \u00d6sterreich und die Schweiz. Die Gesellschaft plant, ihre internationale Pr\u00e4senz weiter auszubauen. Das Gesch\u00e4ftsmodell von Dermapharm umfasst \u00fcberdies ein Parallelimportgesch\u00e4ft, das unter der Marke \u201eaxicorp\u201c betrieben wird. Ausgehend vom Umsatz geh\u00f6rte Dermapharm im ersten Halbjahr 2018 zu den f\u00fcnf umsatzst\u00e4rksten Parallelimporteuren in Deutschland. Mit einer konsequenten Entwicklungsstrategie und zahlreichen erfolgreichen Produkt- und Firmen\u00fcbernahmen in den vergangenen 25 Jahren hat Dermapharm ihre Gesch\u00e4ftsaktivit\u00e4ten kontinuierlich optimiert und neben organischem Wachstum f\u00fcr externe Wachstumsimpulse gesorgt. Diesen profitablen Wachstumskurs beabsichtigt Dermapharm auch in Zukunft fortzuf\u00fchren. Dabei setzt das Unternehmen auf drei Wachstumstreiber: die hausinterne Entwicklung neuer Produkte, die Ausweitung der internationalen Pr\u00e4senz sowie weitere Akquisitionen. Dazu z\u00e4hlt der Erwerb des\r\nArzneimittelherstellers und -vermarkters Trommsdorff im Januar 2018, zu dessen Portfolio beispielsweise die bekannten Marken Keltican\u00ae forte und Tromcardin\u00ae complex geh\u00f6ren.\r\n\r\nCorporate News\r\nKontakt\r\ncometis AG\r\nClaudius Krause\r\nTel.: +49 (0)611 \u2013 205855-28\r\nFax: +49 (0)611 \u2013 205855-66\r\nE-Mail: ir@dermapharm.de\r\n\r\n[\/et_pb_text][et_pb_text admin_label=\"Text\" background_layout=\"light\" text_orientation=\"left\" use_border_color=\"off\" border_color=\"#ffffff\" border_style=\"solid\"]\r\n\r\n<div class=\"leseprobe-archiv\"><a title=\"Beitrag als PDF\" href=\"https:\/\/ir.dermapharm.de\/pdf\/20180912_CN_Dermapharm_H1_2018_finale%20Zahlen.pdf\" target=\"_blank\">Beitrag als PDF<\/a><\/div>\r\n<style>\r\n.leseprobe-archiv {\r\n    color: #00225f !important;\r\n    border-color: #00225f;\r\n    position: relative;\r\n    padding: 0.3em 1em;\r\n    border: 1px solid;\r\n    -webkit-border-radius: 3px;\r\n    -moz-border-radius: 3px;\r\n    border-radius: 3px;\r\n   -webkit-transition: all 0.2s;\r\n    -moz-transition: all 0.2s;\r\n    transition: all 0.2s;\r\n    padding:10px;\r\n    width: 19%;\r\n    text-align: center;\r\n    margin-right: 10px;\r\n    float:left;\r\n}\r\n.leseprobe-archiv:hover {\r\n    background-color: #eee;\r\n    border-color: #ffffff;\r\n    cursor: pointer;\r\n}\r\n<\/style>\r\n\r\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[326,448],"tags":[489],"class_list":["post-18839","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dermapharm-corporate-news-en","category-news-en","tag-489"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>September 12, 2018 | Dermapharm Holding SE publishes report for first half of 2018 - cometis AG<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"September 12, 2018 | Dermapharm Holding SE publishes report for first half of 2018 - cometis AG\" \/>\n<meta property=\"og:description\" content=\"Corporate news to the archive Dermapharm Holding SE publishes report for first half of 2018 Group revenues increased by 19.7% to EUR 280.3 million Adjusted EBITDA rose by 29.9% to EUR 70.9 million; EBITDA margin improved to 25.3% New growth opportunities thanks to the acquisitions of Strathmann and Trommsdorff, organic growth and successfully introduced proprietary [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"cometis AG\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-12T07:00:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-10T04:54:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\" \/>\n\t<meta property=\"og:image:width\" content=\"172\" \/>\n\t<meta property=\"og:image:height\" content=\"174\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Assistenz cometis AG\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Assistenz cometis AG\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/\"},\"author\":{\"name\":\"Assistenz cometis AG\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6\"},\"headline\":\"September 12, 2018 | Dermapharm Holding SE publishes report for first half of 2018\",\"datePublished\":\"2018-09-12T07:00:44+00:00\",\"dateModified\":\"2022-03-10T04:54:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/\"},\"wordCount\":1205,\"publisher\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"keywords\":[\"2018\"],\"articleSection\":[\"Dermapharm Corporate News\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/\",\"url\":\"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/\",\"name\":\"September 12, 2018 | Dermapharm Holding SE publishes report for first half of 2018 - cometis AG\",\"isPartOf\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"datePublished\":\"2018-09-12T07:00:44+00:00\",\"dateModified\":\"2022-03-10T04:54:37+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/#primaryimage\",\"url\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"contentUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"width\":172,\"height\":174,\"caption\":\"Icon Newsroom_news\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#website\",\"url\":\"https:\/\/dev.cometis.de\/de\/\",\"name\":\"cometis AG\",\"description\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"publisher\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dev.cometis.de\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\",\"name\":\"cometis AG\",\"alternateName\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"url\":\"https:\/\/dev.cometis.de\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png\",\"contentUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png\",\"width\":171,\"height\":31,\"caption\":\"cometis AG\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6\",\"name\":\"Assistenz cometis AG\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g\",\"caption\":\"Assistenz cometis AG\"},\"url\":\"https:\/\/dev.cometis.de\/en\/author\/assistenz-cometis-ag\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"September 12, 2018 | Dermapharm Holding SE publishes report for first half of 2018 - cometis AG","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"September 12, 2018 | Dermapharm Holding SE publishes report for first half of 2018 - cometis AG","og_description":"Corporate news to the archive Dermapharm Holding SE publishes report for first half of 2018 Group revenues increased by 19.7% to EUR 280.3 million Adjusted EBITDA rose by 29.9% to EUR 70.9 million; EBITDA margin improved to 25.3% New growth opportunities thanks to the acquisitions of Strathmann and Trommsdorff, organic growth and successfully introduced proprietary [&hellip;]","og_url":"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/","og_site_name":"cometis AG","article_published_time":"2018-09-12T07:00:44+00:00","article_modified_time":"2022-03-10T04:54:37+00:00","og_image":[{"width":172,"height":174,"url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","type":"image\/png"}],"author":"Assistenz cometis AG","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Assistenz cometis AG","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/#article","isPartOf":{"@id":"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/"},"author":{"name":"Assistenz cometis AG","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6"},"headline":"September 12, 2018 | Dermapharm Holding SE publishes report for first half of 2018","datePublished":"2018-09-12T07:00:44+00:00","dateModified":"2022-03-10T04:54:37+00:00","mainEntityOfPage":{"@id":"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/"},"wordCount":1205,"publisher":{"@id":"https:\/\/dev.cometis.de\/de\/#organization"},"image":{"@id":"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","keywords":["2018"],"articleSection":["Dermapharm Corporate News","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/","url":"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/","name":"September 12, 2018 | Dermapharm Holding SE publishes report for first half of 2018 - cometis AG","isPartOf":{"@id":"https:\/\/dev.cometis.de\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/#primaryimage"},"image":{"@id":"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","datePublished":"2018-09-12T07:00:44+00:00","dateModified":"2022-03-10T04:54:37+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/en\/12-september-2018-dermapharm-holding-se-publishes-report-for-first-half-of-2018\/#primaryimage","url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","contentUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","width":172,"height":174,"caption":"Icon Newsroom_news"},{"@type":"WebSite","@id":"https:\/\/dev.cometis.de\/de\/#website","url":"https:\/\/dev.cometis.de\/de\/","name":"cometis AG","description":"Deutschlands f\u00fchrende Investor Relations Agentur","publisher":{"@id":"https:\/\/dev.cometis.de\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.cometis.de\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dev.cometis.de\/de\/#organization","name":"cometis AG","alternateName":"Deutschlands f\u00fchrende Investor Relations Agentur","url":"https:\/\/dev.cometis.de\/de\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/","url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png","contentUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png","width":171,"height":31,"caption":"cometis AG"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6","name":"Assistenz cometis AG","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g","caption":"Assistenz cometis AG"},"url":"https:\/\/dev.cometis.de\/en\/author\/assistenz-cometis-ag\/"}]}},"_links":{"self":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts\/18839","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/users\/24813"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/comments?post=18839"}],"version-history":[{"count":0,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts\/18839\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/media\/54374"}],"wp:attachment":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/media?parent=18839"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/categories?post=18839"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/tags?post=18839"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}